Publications

Gentry PR, Covington TR, Clewell HJ, Andersen ME. 2003. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. J Toxicol Environ Health A 66(23):2209–2225.

Choksi NY, Jahnke GD, St Hilaire C, Shelby MD. 2003. Role of thyroid hormones in human and laboratory animal reproductive health. Birth Defects Res. (B) Develop Reprod Toxicol 68:479–491, DOI: 10.1210/er.2015-1106.

Clewell H, Crump K, Covington T, Gentry R, Yeager J. A risk assessment for inhaled arsenic based on urinary arsenic concentration using a pharmacokinetic model. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2003.

Guo LT, Zhang X, Kuang W, Xu H, Liu LA, Vilquin J-T, et al. (2003) Laminin a2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 13:207–215.

Proctor, D., M. Harris, and D. Rabbe. 2002. Chapter 9: A risk assessment of chromium contaminated soils: ten years of research to characterize the health hazards, in Human and Ecological Risk Assessment: Theory and Practice. D. Paustenbach (ed.). pp. 485–555.

Haws, L. Permitting of Hazardous Waste Combustion Facilities in the State of Texas: Human Health Risks Associated with Fugitive Emissions Sources. Presented at the Texas Chemical Council Quarterly Meeting. August 1, 2002. Houston, TX.

Grant RL, Rodriguez R, Hofelt CS, and Haws LC. 2002. Shortcomings in USEPA’s approach for predicting risk due to consumption of animal food products impacted by air emissions from hazardous waste combustion facilities: a case study involving phthalates. Human Ecol Risk Assess. 8(5):1137-1154.

Sanatamaria, A., L. Ferriby, M. Harris, and D. Paustenbach. Use of biomarkers in health risk assessment. In Toxicologic Biomarkers, Anthony DeCaprio (ed.). Informa Healthcare. pp. 85-109.

Haws, L. Texas Risk Reduction Program Rule-The Basics. Question and Answer Forum Panelist. Presented at the Texas Natural Resource Conservation Commission Environmental Trade Fair. Waste Remediation Track. May 7, 2002. Austin, TX.

Roberts SM, Jordan KE, Warren DA, Britt JK and James RC. 2002. Evaluation of the carcinogenicity of 1,1-Dichloroethylene (Vinylidene Chloride). Regul. Toxicol. Pharmacol. 35:44-55.

Haws, L. Toxicology and Risk Assessment Resources and Practices in the State of Texas. Presented at the USEPA Region 6 States Risk Assessment Roundtable. April 5, 2002. Dallas, TX.

Dressman D, Araishi K, Imamura M, Sasaoka T, Liu LA, Engvall E, Hoffman EP. 2002. Delivery of a- and b-sarcoglycan by recombinant adeno- associated virus: Efficient rescue of muscle, but differential toxicity. Hum Gene Ther 13:1631–1646.

Patel LB, Walden GL, Kaminsky MM, Bailey RE, McMillan DA. Peroxide degradation kinetics during use of Crest Whitestrips. Toxicologist 66(1-S):269, 2002.

Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T, Gentry R, Shipp A. 2002. Review and evaluation of the potential impact of age and gender-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 32(5):329–389.

Perry, C.S. TRRP Rule – The basics part 2: human health PCLs and look-up tables. 2002 TNRCC Environmental Trade Fair presentation and paper.

Hofelt CS, Honeycutt M, McCoy JT, and Haws LC. 2001. Development of a metabolism factor for polycyclic aromatic hydrocarbons for use in multipathway risk assessments for hazardous waste combustion facilities. Reg Toxicol Pharmacol. 33:60-65.

Gentry PR, Covington TR, Andersen ME, Clewell HJ. 2002. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 36:51–68.

Grasty RC, Grey BE, Thibodeaux J, Lau C, Rogers JM. (2002). Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat. The Toxicologist 66 (1-S), 118.